These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29651569)

  • 41. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
    Kim YJ; Kim YI
    Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
    Müller C; Umbricht CA; Gracheva N; Tschan VJ; Pellegrini G; Bernhardt P; Zeevaart JR; Köster U; Schibli R; van der Meulen NP
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1919-1930. PubMed ID: 31134301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radioligand Therapy With
    Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
    AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.
    Calais PJ; Turner JH
    Ann Nucl Med; 2014 Jul; 28(6):531-9. PubMed ID: 24687907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Streamlined Schemes for Dosimetry of
    Kurth J; Heuschkel M; Tonn A; Schildt A; Hakenberg OW; Krause BJ; Schwarzenböck SM
    Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359784
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.
    Ahmadzadehfar H; Rahbar K; Kürpig S; Bögemann M; Claesener M; Eppard E; Gärtner F; Rogenhofer S; Schäfers M; Essler M
    EJNMMI Res; 2015 Dec; 5(1):114. PubMed ID: 26099227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
    Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A
    J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhancing Treatment Efficacy of
    Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol.
    Olmstead C; Cruz K; Stodilka R; Zabel P; Wolfson R
    Nucl Med Commun; 2015 Feb; 36(2):129-34. PubMed ID: 25356620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [
    Ahmadzadehfar H; Schlolaut S; Fimmers R; Yordanova A; Hirzebruch S; Schlenkhoff C; Gaertner FC; Awang ZH; Hauser S; Essler M
    Oncotarget; 2017 Nov; 8(61):103108-103116. PubMed ID: 29262549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands.
    van Kalmthout L; Braat A; Lam M; van Leeuwaarde R; Krijger G; Ververs T; Mehra N; Bins A; Hunting J; de Keizer B
    Clin Nucl Med; 2019 Jun; 44(6):446-451. PubMed ID: 30985436
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
    Tagawa ST; Vallabhajosula S; Christos PJ; Jhanwar YS; Batra JS; Lam L; Osborne J; Beltran H; Molina AM; Goldsmith SJ; Bander NH; Nanus DM
    Cancer; 2019 Aug; 125(15):2561-2569. PubMed ID: 31012963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer.
    Gadot M; Davidson T; Aharon M; Atenafu EG; Malki A; Levartovsky M; Saad A; Domachevsky L; Berger R; Leibowitz R
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32357427
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA damage in blood leucocytes of prostate cancer patients during therapy with
    Schumann S; Scherthan H; Lapa C; Serfling S; Muhtadi R; Lassmann M; Eberlein U
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1723-1732. PubMed ID: 31028426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcome and safety of rechallenge [
    Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
    J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relative Efficacy of
    Lee H
    Mol Imaging Radionucl Ther; 2022 Feb; 31(1):1-6. PubMed ID: 35114745
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [
    Boegemann M; Schrader AJ; Rahbar K
    Urologe A; 2017 Nov; 56(11):1440-1444. PubMed ID: 28986618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.